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Asthma is a chronic inflammatory disease of the airways in which many cell types
play a role, in particular mast cells, eosinophils and T lymphocytes. In susceptible indi-
viduals, inflammation causes recurrent episodes of wheezing, breathlessness, chest tight-
ness and cough, particularly at night and/or early morning. Inflammation causes an as-
sociated increase in airway responsiveness to a variety of stimuli (1). Recruitment of pe-
ripheral blood cells into inflamed airways is the result of adhesive interactions between
circulating inflammatory and microvascular endothelial cells via the production of pro-
inflammatory mediators, cytokines and chemokines, and the expression of cell surface
adhesion molecules (2).
Rebamipide, an amino acid derivative of 2(1H)-quinolinone (Fig. 1), is used for mu-
cosal protection, healing of gastroduodenal ulcers, and treatment of gastritis, colitis and
inflammatory bowel disease (3–5). Rebamipide inhibits the NF-kB, expression of various
adhesion molecules as well as the production of various inflammatory mediators (IL-1a,
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The present investigation was carried out to study the ef-
fect of rebamipide in experimentally induced bronchial
asthma in mice. Trypsin and egg-albumin induced chronic
model of asthma was used and various parameters were
measured on the 35th day. The asthmatic control group
showed lower level of haemoglobin saturation with oxy-
gen, tidal volume, airflow rate and higher respiratory rate,
serum bicarbonate level, eosinophil count in bronchoalveo-
lar lavage fluid and histamine level compared to the nor-
mal control group. Dexamethasone and rebamipide treat-
ed groups showed the return of all the above parameters
towards normal values. Histopathological examination of
lungs showed more prominent alveolar and muscular
layer destruction in the asthmatic control group than in
dexamethasone and rebamipide treated groups. Rebami-
pide showed a beneficial effect and might be used for the
treatment of bronchial asthma.
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IL-8, TNF-a, histamine and leukotrienes) (6, 7). It inhibits mobilization of granulocytes,
macrophages and neutrophils and production of IgG/IgM antibodies (8). In light of the
above facts, the present investigation was carried out to study the potential effect of reba-
mipide in the trypsin and egg-albumin induced experimental model of asthma in mice.
EXPERIMENTAL
Chemicals
Rebamipide was obtained from Macleod Pharmaceuticals, India. Dexamethasone was
obtained from Suvik Pharmaceutical Private Limited, India. Trypsin and egg-albumin
were purchased from Rakesh Chemicals, India. Histamine hydrochloride was procured
from Sigma Chemicals, USA. Saline (0.9 %, m/V, NaCl) and phosphate buffered saline
(pH = 7.2) were used.
Animals
Healthy albino mice of either sex (n = 24), weighing 25–30 g were procured from Zydus
Research Centre, India. The animals were housed at 25 ± 1 °C, 50 ± 15 % RH for 12 hour
light-dark cycles, in polypropylene cages with free access to food and water ad libitum.
The experimental protocol was approved by the Institutional (K. B. Institute of Pharma-
ceutical Education and Research) Animal Ethics Committee (IAEC) under the Committee
for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) guide-
line, before carrying out the project.
Study design
A combination of trypsin and egg-albumin was used to induce asthmatic status in
mice (9). The animals were divided into four groups of six animals each: group I – asthma,
group II – asthma + rebamipide, group III – asthma + dexamethasone, group IV – normal
control.
All animals (except group IV) were exposed to trypsin aerosol (1 mg mL–1, 1 mLmin–1)
once daily for 5 min, followed by a rest of 2 h and then exposed to egg-albumin aerosol
(1 %, m/V, 1 mL min–1) for 3 min. This procedure was repeated for 10 days and later
egg-albumin aerosol was discontinued whereas trypsin exposure was continued until the
21st day. On the 21st day, after last exposure to trypsin, the animals were examined for
the parameters mentioned below. Group I animals were exposed to trypsin and egg-al-
bumin, but did not receive any drug treatment. They served as asthmatic control ani-
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Fig. 1. Chemical structure of rebamipide.
mals. Animals of group II received rebamipide (3 mg kg–1, p.o.) and animals of group III
received dexamethasone (5 mg kg–1, p.o.) from day 22 to day 35. Group IV animals did
not receive any treatment except saline and served as normal controls. On day 35, 2 h af-
ter of the last dose of treatment, only egg-albumin challenge was given.
On day 1 before any exposure (basal value), on day 21 after trypsin exposure and on
day 35 after egg-albumin challenge, the following parameters were measured for each ani-
mal: pO2, lung function (respiratory rate, air flow rate, tidal volume), blood (bicarbonate).
On day 35, in addition to the above parameters, the following parameters were also
measured: bronchoalveolar lavage (BAL), histamine in homogenate of lung tissue and
histopathology of lung tissue.
Measurement of serum bicarbonate. – The method used in the present study to mea-
sure the serum bicarbonate level was slightly modified method described by Godkar (10).
Measurement of respiratory rate, airflow rate and tidal volume. – The measurement was
done with the help of a respiratory volume transducer (11).
Differential leukocyte count in BAL fluid. – On the 35th day, 3 h after the egg-albumin
challenge or just prior to animal death, whichever were earlier, the tracheobronchial tree
was lavaged with 1 mL of saline 3 to 4 times. The fluid was collected and centrifuged at
2000 rpm for 5 min. The supernatant was discarded and the pellet was resuspended in
0.5 mL saline. A thin film of suspended saline was made on a clean grease-free slide and
fixed with methyl alcohol for 3–5 min and dried. Then, a few drops of Geimsa stain in
phosphate buffered saline (pH 6.8) were added and kept for 15 min or more. This was
washed off with tap water and dried. The number of each type of leukocytes was deter-
mined under the microscope at 450× magnification.
Histamine release assay from lung tissues (12, 13) and histopathology of lungs. – On day
35, 3.5 h after the egg-albumin challenge or just prior to death of animals, the animals
were sacrificed, lungs were dissected out and chopped into fragments. Chopped lung
tissues were placed in tubes with 2 mL of ice-cold Ca2+-free Tyrode solution and kept on
ice until further use. Lung tissues (200 mg wet mass) were placed into test tubes. The
test tubes were then supplemented with 1.8 mmol L–1 CaCl2 and incubated for 10 min.
at 37 °C. After that, the lung tissues were incubated with 2 mg L–1 egg-albumin for 15 min
at 37 °C. After 15 min, the reaction was stopped by filtration of the medium through
nylon mesh (100 mm). Histamine in the medium was determined fluorimetrically.
Dissected lungs were used for histopathological study.
Statistical analysis. – Experimental results were expressed as the mean ± SEM (n = 6).
Statistical significance of the difference in parameters amongst groups was determined by
one-way ANOVA followed by Tukey’s multiple range test as well as by paired t-test.
RESULTS AND DISCUSSION
Serum bicarbonate
Challenging of animals with egg-albumin on day 35 of the study showed a signifi-
cant (p < 0.001) higher serum bicarbonate level in the asthmatic control group compared
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to the normal control group, whereas significantly (p < 0.05) lower serum bicarbonate
levels in dexamethasone and rebamipide-treated groups compared to the asthmatic con-
trol group (Table I).
Tidal volume, respiratory rate and airflow rate
Significantly (p < 0.001) lower tidal volume and air flow rate were observed in the
asthmatic control group compared to the normal control group after egg-albumin chal-
lenge but there was a significant (p < 0.001) increase in those parameters in dexametha-
sone and rebamipide-treated animals. In contrast to the tidal volume and air flow rate, a
significantly (p < 0.001) lower respiratory rate was observed in dexamethasone and reb-
amipide-treated groups compared to the asthmatic control group (Table I).
BAL fluid
Challenging of animals with trypsin and egg-albumin showed significantly (p < 0.001)
higher eosinophil count in the asthmatic control group compared to the normal control
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Table I. Effect of dexamethasone and rebamipide on serum bicarbonate level, respiratory rate, airflow rate
and tidal volume
Parameter Group I Group II Group III Group IV
Serum bicarbonate level (mmol L–1) 48.83 ± 2.39 34.33 ± 1.17a 35.50 ± 0.56a 34.00 ± 1.24b
Respiratory rate (breaths per min) 193.33 ± 2.01 143.50 ± 7.79c 155.83 ± 3.07c 168.67 ± 4.66c
Air-flow rate (mL min–1) 0.96 ± 0.05 7.29 ± 0.55c 7.92 ± 0.41c 11.26 ± 0.32c
Tidal volume (mL) 0.02 ± 0.01 0.05 ± 0.02c 0.05 ± 0.01c 0.07 ± 0.02c
Values represent mean ± SEM of six animals in each group.
Group I – asthma, group II – dexamethasone (5 mg kg–1), group III – rebamipide (3 mg kg–1), group IV – normal
control.
Significant difference vs. group I: a p < 0.05, b p < 0.01, c p < 0.001.
Fig. 2. Effect of dexamethasone and rebamipide on eosinophil count in BAL fluid. Values represent
mean ± SEM of six animals in each group. Group I – asthma, group II – dexamethasone (5 mg kg–1),
group III – rebamipide (3 mg kg–1), group IV – normal control. Significant difference vs. group
I: *p < 0.001.
group on the 35th day of study. Also, there was a significant (p < 0.001) decrease in eosino-
phil count in the animals subjected to dexamethasone and rebamipide (Fig. 2).
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Fig. 3. Effect of dexamethasone and rebamipide on histamine concentration. Values represent mean
± SEM of six animals in each group. Group I – asthma, group II – dexamethasone (5 mg kg–1),
group III – rebamipide (3 mg kg–1), group IV – normal control. Significant difference between
groups I and IV: *p < 0.001.
Fig. 4. Histopathology of lung: a) normal control mice, b) asthmatic mice, c) dexamethasone-treated
mice, and d) rebamipide-treated mice (magnification 400×, hematoxylin stain).
Histamine release
Significantly (p < 0.001) higher histamine level was observed in the asthmatic control
group compared to the normal control group, but in the animals subjected to rebamipide
treatment, the histamine level decreased compared to the asthmatic control group (Fig. 3).
Histopathology of lungs
Normal control animals showed an intact bronchial structure (Fig. 4a), whereas tryp-
sin and egg-albumin-sensitized animals showed marked inflammation and destruction
of bronchial wall lining (Fig. 4b). Dexamethasone and rebamipide treated animals show-
ed minimal destruction in bronchial wall compared to the asthmatic control group (Figs.
4c and 4d).
CONCLUSIONS
It can be concluded that rebamipide has beneficial effects in trypsin and egg-albu-
min induced experimental bronchial asthma and might be used for its treatment. Fur-
ther clinical research of rebamipide will be necessary to support the present investiga-
tion.
REFERENCES
1. NHLBI, National Asthma Education and Prevention program, Expert Panel Report 2. Guidelines for
the Management of Asthma, US Department of Health and Human Services, NIH publication no:
97, 1997.
2. S. N. Georas, M. C. Liu, W. Newman, L. D. Beall, B. A. Stealey and B. S. Bochner, Altered adhe-
sion molecule expression and endothelial cell activation accompany the recruitment of human
granulocytes to the lung after segmental antigen challenge, Am. J. Respir. Cell Mol. Biol. 7 (1992)
261–269.
3. R. M. Genta, Review article: The role of rebamipide in the management of inflammatory disease
of the gastrointestinal tract, Aliment. Pharm. Therap. 18 (2003) 8–13; DOI: 10.1046/j.1365-2036.
18.s1.5.
4. Y. H. Kim, H. G. Hwang and Y. T. Chung, Rebamipide protects colonic damage induced by tri-
nitrobenzene sulfonic acid (TNBS) via down-regulation of TNF-a, IL-1a‚ And ICAM-1, Korean J.
Anat. 37 (2004) 149–155.
5. L. Kruidenier and H. W. Verspaget, Antioxidants and mucosa protectives: realistic therapeutic
options in inflammatory bowel disease, Mediators Inflamm. 7 (1998) 157–162; DOI: 0962-9351/
98/030157-06.
6. C. D. Kim, Y. K. Kim and S. H. Lee, Rebamipide inhibits neutrophil adhesion to hypoxia/re-
oxygenation stimulated endothelial cells via nuclear factor-kB dependent pathway, J. Pharmacol.
Exp. Ther. 294 (2000) 864–869; DOI: 0022-3565/00/2943-0864.
7. J. Y. Ro, J. Y. Kim and K. H. Kim, The inhibitory mechanism of rebamipide on the mediator
release in the guinea pig lung mast cells activated with specific antigen-antibody reactions, Phar-
macology 63 (2001) 175–184; DOI: 10.1159/000056130.
432
P. Gohil et al.: Preliminary studies on the effect of rebamipide against the trypsin and egg-albumin induced experimental model of
asthma, Acta Pharm. 61 (2011) 427–433.
8. S. Matsumoto, K. Tsuji and S. Shirahama, Rebamipide enema therapy for left-sided ischemic
colitis patients accompanied by ulcers: Open label study,World J. Gastroenterol. 14 (2008) 4059–4064;
DOI: 10.3748/wjg.14.4059.
9. S. Shah, G. Shah G and P. Gohil, Role of estrogen receptor-a in an experimental model of bron-
chial asthma, Iranian Biomed. J. 14 (2010) 41–48.
10. P. B. Godkar, Acid-base Balance, in Textbook of Medical Laboratory Technology, 11th ed., Bhalani Pub-
lishing House, New Delhi 1996, pp. 252–257.
11. R. Khandpur, Pulmonary function analyzer, in Handbook of Biomedical Instrumentation, 1st ed., Tata
McGraw-Hill Publishing Company, New Delhi 1996, pp. 308–333.
12. R. Singh, A. Nath, A. A. Gupta, M. Shukla, S. K. Khare and B. Kundu, Antiallergic/antiasthma-
tic effect of novel antiallergic hexapeptide-95-220 in various experimental models, Indian J. Exp.
Biol. 39 (2001) 871–877.
13. P. A. Shore, A. Burkhalter and V. H. Cohn, Amethod for the fluorometric assay of the histamine
in tissues, J. Pharmacol. Exp. Ther. 127 (1959) 182–186.
S A @ E T A K
Preliminarno ispitivanje djelovanja rebamipida na model astme
inducirane tripsinom i albuminom jajeta
PRIYANSHEE GOHIL, HIMANI THAKKAR, UNNATI GOHIL i SHRIKALP DESHPANDE
U radu je ispitivano djelovanje rebamipida na eksperimentalno induciranu bronhi-
jalnu astmu u mi{eva. Astma uzrokovana tripsinom i albuminom jajeta model je kroni-
~ne astme. Nakon 35. dana mjereni su razli~iti parametri. Kontrolna skupina s astmom
imala je ni`u koncentraciju oksihemoglobina, di{ni volumen, protok zraka, koncentra-
ciju SOD-a, a ve}i broj udisaja i izdisaja, koncentraciju bikarbonata u serumu, broj eozi-
nofila u BAL fluidu i ve}u koncentraciju histamina u odnosu na kontrolnu skupinu bez
astme. Skupina `ivotinja tretirana deksametazonom i rebamipidom imala je ve}i pO2,
di{ni volumen, protok zraka i koncentraciju SOD-a, a smanjenu respiraciju, koncentra-
ciju bikarbonata, broj eozinofila u BAL teku}ini i koncentraciju histamina u odnosu na
kontrolnu skupinu s astmom. Histopatolo{ka ispitivanja plu}a pokazala su ja~e izra`ena
o{te}enja alveola i mi{i}nog sloja u kontrolnoj skupini s astmom nego u skupini tretira-
noj deksametazonom i rebamipidom. Rebamipid je imao povoljan u~inak na astmati~nu
skupinu i mogao bi se upotrijebiti u terapiji bronhalne astme.
Klju~ne rije~i: astma, rebamipid, tripsin, histamin
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